MONDAY, July 31, 2006 (HealthDay News) -- Barrier Therapeutics' treatment for seborrheic dermatitis has been approved by the U.S. Food and Drug Administration, the company said in a statement.
Xolegel (2% ketoconazole, USP) is a once-daily topical gel to treat the skin condition, characterized by a red, scaly, itchy rash that primarily develops on the face, scalp, hairline, eyebrows and trunk.
Seborrheic dermatitis affects 3 percent to 5 percent of the U.S. population, or about 8.5 million people, the company said. The condition often recurs, requiring additional treatment.
To learn more about seborrheic dermatitis, visit the American Academy of Family Physicians.